Hepatitis C virus infection and rituximab therapy after renal transplantation

Fabrizi Fabrizio, P. Martin, A. Elli, G. Montagnino, G. Banfi, P. Passerini, M. R. Campise, A. Tarantino, C. Ponticelli

Research output: Contribution to journalArticlepeer-review


Background. Rituximab, a chimeric monoclonal antibody, has been successfully given in various diseases including HCV-associated mixed cryoglobulinemia. However, only preliminary data exists on its efficacy and safety after renal transplantation. Methods. We report on a renal transplant recipient with chronic hepatitis C who received rituximab therapy for gastric cancer. Four rituximab infusions of 375 mg/m2 were given. Results. Rituximab therapy was complicated by cholestatic hepatitis C with very high HCV RNA levels; liver insufficiency occurred. The patient developed bacterial pneumoniae and respiratory insufficiency was the cause of death. Although other mechanisms cannot be excluded, we found that rituximab therapy was implicated in the pathogenesis of cholestatic hepatitis C in our patient. Conclusions. We suggest that rituximab therapy may be associated with significant side effects. More experience has to be accumulated before any conclusions on efficacy and safety of rituximab therapy after RT can be drawn.

Original languageEnglish
Pages (from-to)445-449
Number of pages5
JournalInternational Journal of Artificial Organs
Issue number5
Publication statusPublished - May 2007


  • Gastric cancer
  • Hepatitis C
  • Renal transplant
  • Rituximab

ASJC Scopus subject areas

  • Biophysics


Dive into the research topics of 'Hepatitis C virus infection and rituximab therapy after renal transplantation'. Together they form a unique fingerprint.

Cite this